Upon joining the study, the patient will begin the initial treatment phase. This involves receiving medications through an intravenous infusion.

The medications include sacituzumab govitecan and pembrolizumab. Sacituzumab govitecan is administered as a 200 mg powder for solution, and pembrolizumab is given as a 25 mg/mL concentrate for solution.

The frequency and duration of these infusions will be determined by the study protocol and the treating physician.

In addition to the initial medications, the patient may receive treatment of the physician’s choice, which could include other medications such as paclitaxel, carboplatin, or gemcitabine.

Paclitaxel is provided as a 6 mg/mL concentrate, carboplatin as a 10 mg/mL concentrate, and gemcitabine as a 38 mg/mL concentrate, all for intravenous infusion.

The specific choice of medication and its administration schedule will be tailored to the patient’s condition and response to treatment.

Throughout the trial, the patient’s progress will be monitored through regular assessments. These assessments will evaluate the effectiveness of the treatment and any side effects experienced.

The primary goal is to measure progression-free survival, which is the time from the start of treatment until the disease progresses or the patient passes away.

Secondary assessments will include overall survival, response rates, and the duration of response, among other health and quality of life measures.

The trial is expected to continue until February 2027, with the patient’s participation lasting as long as the treatment is beneficial and safe.

Upon completion, the patient’s overall health and treatment outcomes will be reviewed to determine the next steps in their care.